Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
- 10.2991/chi.d.190219.001How to use a DOI?
- CAR-T cells; Acute lymphoblastic leukemia; CD19; Non-Hodgkin's lymphoma
Application of immunotherapeutic modalities changed paradigms in the treatment of hematologic malignancies, with regards to drug manufacturing, treatment protocols, short- and long-term toxicities. FDA-approved therapies, including blinatumomab, tisagenlecleucel, and axicabtagene ciloleucel, target T cells to attack healthy and malignant cells expressing CD19, leading to high response rates in previously heavily treated patients, and to durable remissions in the absence of further therapies. Nevertheless, despite paucity of long-term data, some patients are resistant to these agents, and many relapse. This review will discuss the mechanisms of failure of these immune-based therapies, and offer guidelines to the practicing physician.
- © 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
- Open Access
- This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
Download article (PDF)
View full text (HTML)
Cite this article
TY - JOUR AU - Elad Jacoby PY - 2019 DA - 2019/06/11 TI - Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies JO - Clinical Hematology International SP - 79 EP - 84 VL - 1 IS - 2 SN - 2590-0048 UR - https://doi.org/10.2991/chi.d.190219.001 DO - 10.2991/chi.d.190219.001 ID - Jacoby2019 ER -